time for news, page-8

aridol endorsed in australian guidelines ARIDOL ENDORSED IN GLOBAL AND AUSTRALIAN GUIDELINES
Pharmaceutical company Pharmaxis (ASX:PXS, NASDAQ:PXSL) today announced that
its first commercial product Aridol has been included in both global and Australian
official guidelines for managing asthma.
Aridol’s inclusion in the two influential guidelines: the GINA Report on Global Strategy
for Asthma Management and Prevention, and the Australian Asthma Management
Handbook, follows extensive independent scientific and clinical review.
Alan Robertson, Pharmaxis CEO, said: “We are delighted that Aridol is recognised and
endorsed by both global and Australian experts as a significant addition to the tools
available to help asthma patients. Inclusion in both national and international
guidelines after exhaustive independent peer review is particularly gratifying, and will
accelerate the acceptance of Aridol by physicians worldwide.”
Aridol is recommended in both guidelines as a lung function test that physicians can
undertake to diagnose asthma in patients.
The Global Initiative for Asthma (GINA) is a network of individuals, organisations and
public health officials who disseminate information about the optimal care of patients
with asthma, incorporating the latest research and best clinical practice. This latest
report is a direct response by GINA to several recent international surveys which
have highlighted that asthma control remains poor. It incorporates updated scientific
information (including Aridol) and promotes an approach to asthma management
based on asthma control, rather than asthma severity. This is important since Aridol
has recently become the first bronchial challenge test to be approved in a European
country as an aid to asthma control.
Australia’s new asthma management guidelines were launched yesterday by the
Parliamentary Secretary for the Minister for Health and Ageing, Christopher Pyne.
Published as the National Asthma Council Australia’s Asthma Management Handbook,
the guidelines are the gold standard of practice for asthma management in Australia.
They are updated regularly to accommodate changes in asthma management, based
on the latest medical evidence and new treatments that become available, as well as
reflecting current areas of consumer concern.